跳至主要内容
临床试验/NCT03869671
NCT03869671
撤回
不适用

Optimizing Bio-behavioral HIV Prevention Approaches for People Who Inject Drugs

Boston University0 个研究点2021年3月

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Intravenous Drug Abuse
发起方
Boston University
主要终点
PrEP uptake by self-report
状态
撤回
最后更新
5年前

概览

简要总结

People who inject drugs (PWID) experience high risk of HIV acquisition. Antiretroviral pre-exposure prophylaxis (PrEP) is an efficacious biomedical HIV prevention strategy for high risk HIV-uninfected individuals including PWID, yet uptake has been low in this population and uptake and adherence interventions have not been developed or tested. Drawing from formative qualitative research, the overall goal of this project is to develop an intervention to promote PrEP uptake and adherence among PWID in the U.S. Northeast. The investigators will:

  • Analyze existing literature and data to identify specific barriers and facilitators to PrEP uptake and adherence among PWID to inform the initial adaptation of existing theory-based interventions;
  • Conduct qualitative interviews with ~30 PWID and ~10 key informants (PrEP and other clinical and social service providers) to identify intervention targets;
  • Develop and iteratively refine and finalize an intervention manual based on feedback from qualitative exit-interviews with an interventionist and ~10 PWID; and
  • Conduct a pilot randomized clinical trial (RCT) in ~50 HIV-uninfected PWID to compare PrEP uptake and adherence outcomes and assess intervention feasibility and acceptability.

详细描述

This mixed methods phased research will use qualitative and quantitative techniques to improve PrEP uptake and adherence among PWID through the following three phases: * Phase 1 will identify the modifiable determinants of PrEP uptake and adherence among HIV-uninfected PWID using in-depth qualitative interviews with PWID and key informants (KIs). Qualitative interviews will explore perceived acceptability and identify barriers and facilitators to PrEP uptake and adherence among \~30 HIV-uninfected PWID and explore perspectives on optimal PrEP delivery methods with \~15 KIs (e.g., PrEP physicians, community-based organization staff members with experience working with PWID). * Phase 2 will involve identifying intervention targets and adapting existing intervention strategies to improve PrEP uptake and adherence among PWID. This will involve reviewing the literature to identify and select components of existing, evidence-based medication adherence interventions to adapt for the unique determinants of PrEP uptake and adherence among PWID. Investigators will then develop and iteratively refine and finalize an intervention manual by conducting an open-pilot of the intervention in a community-based setting. Refinements will be based on feedback from qualitative exit-interviews with the interventionist and \~10 PWID. * Phase 3 will involve pilot testing the resulting PrEP uptake and adherence intervention in a selected community-based setting to obtain preliminary data on PrEP uptake and adherence outcomes (primary outcomes) and intervention feasibility and acceptability (secondary outcomes). Investigators will use a pilot RCT design with a mixed methods process evaluation in which 50 HIV-uninfected PWID will be randomized to the PrEP intervention or a control condition (SEP standard of care; n=25 per arm). Investigators will assess changes in PrEP outcomes (primary outcomes of uptake and adherence) and key implementation measures (e.g., secondary outcomes of acceptability, feasibility, adoption by the interventionist).

注册库
clinicaltrials.gov
开始日期
2021年3月
结束日期
2022年3月
最后更新
5年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • An adult PWID
  • Self report of any high risk behaviors for HIV (past-month receptive syringe sharing, transactional sex, condomless sex with an HIV-infected or unknown status partner)

排除标准

  • Unable or unwilling to provide informed consent
  • For Phase 3 (the RCT pilot):
  • Inclusion Criteria:
  • Clinically eligible for PrEP (confirmed HIV-uninfected status, adequate renal function \[estimated creatinine clearance ≥60 ml/min\], and documented hepatitis B virus \[HBV\] status)

结局指标

主要结局

PrEP uptake by self-report

时间窗: 3 months

measured using 1 item in a structured questionnaire

PrEP uptake by pharmacy records

时间窗: 3 months

measured by accessing pharmacy records

PrEP adherence by self-report

时间窗: 3 months

measured using 1 item in a structured questionnaire to determine the proportion of doses taken as prescribed

PrEP adherence by dried blood spot

时间窗: 3 months

measured via detection of tenofovir and emtricitabine in dried blood spots (DBS)

次要结局

  • Interventionist satisfaction with training materials(1 month)
  • Interventionist satisfaction with intervention content(1 month)
  • Interventionist satisfaction with intervention delivery methods(1 month)
  • Interventionist satisfaction with intervention manual(1 month)
  • Participant satisfaction with intervention content(1 month)
  • Participant satisfaction with intervention delivery methods(1 month)

相似试验